MARKET

VIR

VIR

Vir Biotechnology, Inc.
NASDAQ
7.19
+0.27
+3.90%
After Hours: 7.35 +0.16 +2.23% 19:46 02/06 EST
OPEN
7.06
PREV CLOSE
6.92
HIGH
7.40
LOW
7.04
VOLUME
1.86M
TURNOVER
--
52 WEEK HIGH
10.67
52 WEEK LOW
4.155
MARKET CAP
1.00B
P/E (TTM)
-1.9861
1D
5D
1M
3M
1Y
5Y
1D
Vir Biotechnology: The Low-Down On The Readouts Ahead
Seeking Alpha · 1d ago
VIR BIOTECHNOLOGY <VIR.O>: BARCLAYS CUTS TARGET PRICE TO $24 FROM $31
Reuters · 2d ago
Vir Biotechnology price target lowered to $24 from $31 at Barclays
TipRanks · 2d ago
Barclays Keeps Their Buy Rating on Vir Biotechnology (VIR)
TipRanks · 3d ago
U.S. RESEARCH ROUNDUP- Ametek, Coca-Cola, Pepsico
Reuters · 3d ago
Vir Biotechnology Director Vicki L. Sato Reports Disposal of Common Shares
Reuters · 3d ago
Did Vir's Advancing Hepatitis D Combo Program Just Shift Vir Biotechnology's (VIR) Investment Narrative?
Simply Wall St · 4d ago
Weekly Report: what happened at VIR last week (0126-0130)?
Weekly Report · 4d ago
More
About VIR
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.

Webull offers Vir Biotechnology Inc stock information, including NASDAQ: VIR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VIR stock methods without spending real money on the virtual paper trading platform.